0.2955
-0.0145
(-4.68%)
At close: April 15 at 9:00:34 PM GMT+2
Research Analysis
Earnings Estimate
Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
No. of Analysts | -- | -- | -- | -- |
Avg. Estimate | 0 | 0 | 0 | 0 |
Low Estimate | 0 | 0 | 0 | 0 |
High Estimate | 0 | 0 | 0 | 0 |
Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
Currency in SEK | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
No. of Analysts | 1 | 1 | 5 | 5 |
Avg. Estimate | 12M | 18M | 284.73M | 430.87M |
Low Estimate | 12M | 18M | 90M | 228.82M |
High Estimate | 12M | 18M | 573.54M | 707.7M |
Year Ago Sales | 12.1M | 13.9M | 46.1M | 284.73M |
Sales Growth (year/est) | -0.83% | 29.50% | 517.63% | 51.33% |
EPS Trend
Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
Current Estimate | 0 | 0 | 0 | 0 |
7 Days Ago | 0 | 0 | 0 | 0 |
30 Days Ago | 0 | 0 | 0 | 0 |
60 Days Ago | 0 | 0 | 0 | 0 |
90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
Current Qtr. | Next Qtr. | Current Year | Next Year | |
---|---|---|---|---|
P0F.F | -- | -- | -- | -- |
S&P 500 | 6.76% | 5.73% | 9.19% | 14.14% |
Related Tickers
ARDX.MX Ardelyx, Inc.
105.50
0.00%
B9A.F BioArctic AB (publ)
16.79
+12.46%
HQ1.MU Oruka Therapeutics Inc. R
7.05
+6.02%
RPD.MU Royalty Pharma plc
28.20
0.00%
BT3.BE Lineage Cell Therapeutics Inc
0.3800
-5.47%
7PO.F Poxel S.A.
0.4510
-11.39%
05Y.MU Vivoryon Therapeutics NV
1.7440
-4.49%
PROT Proteonomix, Inc.
0.0000
0.00%
ICY.HA Incyte Corp
52.14
+1.76%
2HA.F Spero Therapeutics, Inc.
0.6170
+16.64%